EGFR and lung cancer: Indeed, treatment with the EGFR inhibitor erlotinib reduced growth of EGFR-mutated lung cancer cell lines but favored stem-cell-like phenotype by enhancing Notch3 activation, while addition of GSI prevented selection of CSC, suggesting combined inhibition of EGFR and Notch3 in EGFR-mutated lung cancer as an optimal strategy to counteract the drug resistance mechanism [328].